Premium
Oral etoposide in the treatment of hormone‐refractory prostate cancer
Author(s) -
Hussain Maha H.,
Pienta Kenneth J.,
Redman Bruce G.,
Cummings Glenn D.,
Flaherty Lawrence E.
Publication year - 1994
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19940701)74:1<100::aid-cncr2820740118>3.0.co;2-k
Subject(s) - medicine , etoposide , refractory (planetary science) , prostate cancer , chemotherapy , prostate , cancer , oncology , hormone , hormone therapy , urology , surgery , gastroenterology , physics , astrobiology , breast cancer
Background. Hormone‐refractory prostate cancer generally remains a chemotherapy‐resistant tumor and therefore warrants the continued evaluation of promising agents. Methods. Twenty‐two eligible patients with hormone‐refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m 2 /day for 21 days in a 28‐day cycle. Response was evaluated using standard solid tumor response criteria. Results. There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overal 1‐year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted. Conclusions. Single‐agent oral etoposide has minimal activity in patients with hormone‐refractory prostate cancer.